ArticleNucleic acid therapeutics2016
A High-Throughput Method for Direct Detection of Therapeutic Oligonucleotide-Induced Gene Silencing In Vivo.
Article in Nucleic acid therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 43 citations in OpenAlex.
- Single-dose administration of therapeutic divalent siRNA targeting MECP2 prevents lethality in an MECP2 duplication mouse model.Nature communications · 2026Article
- Precision RNAi for Fibrodysplasia Ossificans Progressiva: a combinatorial, unimolecular, allele selective approach.Research square · 2026Article
- Model selection in preclinical nucleic acid therapeutics research.Communications biology · 2026Review
- Enhancing siRNA efficacy in vivo with extended nucleic acid backbones.Nature biotechnology · 2025Article
- Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo.Nucleic acids research · 2024Article
- Dendritic amphiphilic siRNA: Selective albumin binding,Molecular therapy. Nucleic acids · 2023Article
- Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin.Nature communications · 2023Article
- Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Engineered ionizable lipid siRNA conjugates enhance endosomal escape but induce toxicity in vivo.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Quantitative Measurement of Cytosolic and Nuclear Penetration of Oligonucleotide Therapeutics.ACS chemical biology · 2022Article
- Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Cell Type Impacts Accessibility of mRNA to Silencing by RNA Interference.Molecular therapy. Nucleic acids · 2020Article
- The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy.Nucleic acids research · 2020Article
- Extensive Expression Analysis of Htt Transcripts in Brain Regions from the zQ175 HD Mouse Model Using a QuantiGene Multiplex Assay.Scientific reports · 2019Article
- The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways.Nucleic acids research · 2019Article
- Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo.Nucleic acids research · 2019Article
- Exosomes Produced from 3D Cultures of MSCs by Tangential Flow Filtration Show Higher Yield and Improved Activity.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Preclinical development of RNA interference (RNAi)-based therapeutics requires a rapid, accurate, and robust method of simultaneously quantifying mRNA knockdown in hundreds of samples. The most well-established method to achieve this is quantitative real-time polymerase chain reaction (qRT-PCR), a labor-intensive methodology that requires sample purification, which increases the potential to introduce additional bias. Here, we describe that the QuantiGene(®) branched DNA (bDNA) assay linked to a 96-well Qiagen TissueLyser II is a quick and reproducible alternative to qRT-PCR for quantitative analysis of mRNA expression in vivo directly from tissue biopsies. The bDNA assay is a high-throughput, plate-based, luminescence technique, capable of directly measuring mRNA levels from tissue lysates derived from various biological samples. We have performed a systematic evaluation of this technique for in vivo detection of RNAi-based silencing. We show that similar quality data is obtained from purified RNA and tissue lysates. In general, we observe low intra- and inter-animal variability (around 10% for control samples), and high intermediate precision. This allows minimization of sample size for evaluation of oligonucleotide efficacy in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.